Files relating to the HFEA licenses R0136 for the projects 'Platform technologies underpinning human embryonic stem cell derivation' and 'Derivation of research and therapeutic grade human embryonic stem cells'
- Reference:GB 237 Coll-1320/2/5/2
- Dates of Creation:2001-2007
- Physical Description:7 Files
Scope and Content
Files 1-2 (2001-2004) contain: papers concerning HFEA license for the project 'Platform technologies underpinning human embryonic stem cell derivation' at Roslin Institute under Paul De Sousa and Ian Wilmut, including a copy of the license and correspondence with the HFEA and collaborators in other institutions; correspondence with the HFEA about their pilots for Alerts and for patient information and consent forms for donating gametes or embryos for research; a copy of the HFEA Licensed Embryos Research Centre progress report for Roslin Institute; information and correspondence concerning the HFEA site visit on 6 December 2002. Also present is a copy of the transcript from the hearing of the cross-appeal between the Pro-Life Alliance and the Secretary of State for Health concerning cell nuclear replacement (CNR) embryos.
Files 3-5 (2002-2005) contain: a copy of license R0136-1-a, application forms to the HFEA and to the Joint UCL/UCLH Committees on the Ethics of Human Research Ethics Committee, and related correspondence.
Files 6-7 (2007) relate to Roslin Institute's application for a renewal of the license RO136 for the project 'Derivation of research and therapeutic grade human embryonic stem cells.'Administrative / Biographical History
The project 'Platform technologies underpinning human embryonic stem cell derivation' operated from Roslin Institute's Division of Gene Expression and Development, of which Ian Wilmut was then Head. The project, led by Paul De Sousa, and which necessitated the use for research of oocytes and embryos, aimed to develop methods to derive human embryonic stem (hES) cells from fresh or frozen embryos which were surplus to IVF and preimplantation genetic diagnosis treatment, or parthenogenetic embryos originating from eggs matured in vitro; and to derive and maintain hES cells in a culture environment free of animal cell products. Roslin Institute first acquired a HFEA license for this project in July 2003. In February 2004, a variation to the license was granted to permit embryo donors to consent to the possible future therapeutic use of newly derived stem cells (R0136-1-b).
The project 'Derivation of research and therapeutic grade human embryonic stem cells', led by Paul De Sousa, began in July 2007 and aimed to derive and market research therapeutic-grade human embryonic stem cells under the not-for-profit company Roslin Cells Ltd.Access Information
These files are closed.
Subjects
Corporate Names